A recent study indicates that people who stop using new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight much more quickly than those who stop traditional lifestyle regimens.
Findings released in a prominent health publication points out that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"People using such medications should be informed of the risk of fast rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass within about a year and a half.
Weighing Approaches
The research, which examined dozens of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers point out that individuals who lose weight through diet and exercise usually experience a slower weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Nutrition scientists propose the way of the jabs is key to understanding the amplified regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels far above than normal might result in the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
Medical guidelines recommend the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.
A number of clinicians argue that, considering the likelihood of weight regain, the therapy should be considered ongoing.
This perspective is reinforced by drug manufacturers, who state that the results "highlight the persistent character of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
People who have stopped the medication describe a sudden return of hunger.
"It felt as if a trigger flipping and I was suddenly ravenous," said one woman.
This challenge is worsened if patients have not developed permanent lifestyle or habit modifications during treatment.
Widespread Adoption
Recent estimates show that millions of adults in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is greater among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone solution and lasting health benefits hinges on combined lifestyle support.
